

ESMO-THE CHRISTIE PRECEPTORSHIP PROGRAMME LUNG CANCER

Multidisciplinary management, standards of care and future perspectives

**Manchester, United Kingdom
6-8 March 2019**

CO-CHAIRS:

Fiona Blackhall, United Kingdom
Raffaele Califano, United Kingdom

SPEAKERS:

Mo Al Aloul, United Kingdom
Paul Baas, Netherlands
Haval Balata, United Kingdom
Neil Bayman, United Kingdom
Richard Booton, United Kingdom
David Cobben, United Kingdom
Clara Chan, United Kingdom
Simon Ekman, Sweden
Martin Früh, Switzerland
Pilar Garrido, Spain
Keith M. Kerr, United Kingdom
Rohit Kochhar, United Kingdom
Jaroslaw Kuzdzal, Poland

Cecile Le Péchoux, France
Catherine McBain, United Kingdom
Ugo Pastorino, Italy
Luis Paz-Ares, Spain
David Planchard, France
Martin Reck, Germany
Suresh Senan, Netherlands
Hamid Sheikh, United Kingdom
Tora S. Solheim, Norway
Yvonne Summers, United Kingdom
Paul Taylor, United Kingdom
Paul E. Van Schil, Belgium
David Woolf, United Kingdom

LEARNING OBJECTIVES

- To learn about the evidence-base for lung cancer screening and novel diagnostic modalities
- To learn about the management of early stage NSCLC and use of adjuvant treatments
- To understand the role of multi-modality treatment in locally advanced NSCLC and limited stage SCLC
- To learn about the management of patients with actionable driver mutations and novel targeted agents for advanced NSCLC
- To understand the role of immune-checkpoint blockade for lung cancer and to learn about novel immunotherapies
- To learn about treatment of NSCLC with oligometastatic disease
- To learn about the systemic treatment of mesothelioma and SCLC
- To learn about the role of supportive and palliative care for thoracic malignancies

Wednesday, 6 March 2019

08:15-09:15 60'	Registration	
09:15-10:55 100'	SESSION 1 Screening and diagnostics for lung cancer	Chairs: Raffaele Califano, UK Keith M. Kerr, UK
40'	Lung cancer screening: Pro and Contra	Haval Balata, UK
30'	EBUS TBNA in diagnosis/staging of lung cancer	Richard Booton, UK
30'	Role of pathologist in diagnosis and mutation analysis of lung cancer	Keith M. Kerr, UK

10:55-11:15	Coffee break	
11:15-12:15 60'	SESSION 1 Screening and diagnostics for lung cancer - cont.	Chairs: Fiona Blackhall, UK Raffaele Califano, UK
30'	PET/CT in staging of lung cancer	Rohit Kochhar, UK
30'	Medical thoracoscopy in the management of thoracic malignancies	Mo Al Aloul, UK
12:15-13:15	Lunch	
13:15-14:15 60'	SESSION 2 Radical treatment of early stage NSCLC	Chairs: Cecile Le Pécoux, FR Ugo Pastorino, IT
30'	Surgery for early stage NSCLC	Ugo Pastorino, IT
30'	Adjuvant radiotherapy for completely resected early stage NSCLC	Cecile Le Pécoux, FR
14:15-14:35	Coffee Break	
14:35-15:05 30'	SESSION 2 Radical treatment of early stage NSCLC – cont.	Chairs: Cecile Le Pécoux, FR Ugo Pastorino, IT
30'	Adjuvant chemotherapy for resected early stage NSCLC	Paul Taylor, UK
15:05-15:15 10'	Close of day 1	Chairmen

Thursday, 7 March 2019

09:05-11:05 120'	SESSION 3 Advanced NSCLC	Chair: Suresh Senan, NL
30'	Stereotactic ablative RT for early stage NSCLC	Suresh Senan, NL
30'	1 st line chemotherapy for advanced NSCLC	David Planchard, FR
30'	1 st line Immune-checkpoint blockade for NSCLC	Luis Paz-Ares, ES
30'	2 nd line treatment for advanced NSCLC	Martin Reck, Germany
11:05-11:25	Coffee break	
11:25-13:25 120'	SESSION 3 Advanced NSCLC - cont.	Chairs: Yvonne Summers, UK Fiona Blackhall, UK
30'	Treatment of EGFR mutant advanced NSCLC	Raffaele Califano, UK
30'	Treatment of ALK positive advanced NSCLC	Fiona Blackhall, UK
30'	Maintenance treatment for advanced NSCLC	Yvonne Summers, UK
30'	Beyond ALK and EGFR: Novel molecularly driven targeted therapies in NSCLC	Simon Ekman, SE
13:25-14:30	Lunch	
14:30-16:00 90'	SESSION 4 Palliative treatment of lung cancer and mesothelioma	Chairs: Catherine McBain, UK Paul Baas, NL
30'	Systemic treatment of mesothelioma	Paul Baas, NL
30'	Treatment of oligometastatic NSCLC	Jaroslawn Kuzdzal, PL
30'	Radical treatment of brain metastases: The importance of a neuro-oncology multi-disciplinary approach	Catherine McBain, UK

16:00-16:20	Coffee break	
16:20-17:20 60'	SESSION 4 Palliative treatment of lung cancer and mesothelioma - cont.	Chairs: Raffaele Califano, UK Tora S. Solheim, NO
30'	Supportive and palliative care in lung cancer	Tora S. Solheim, NO
30'	Intra-luminal radiotherapy	Hamid Sheikh, UK
17:20-17:30 10'	Close of day 2	Chairmen
19:00	Welcome drink	
19:30	Dinner	

Friday, 8 March 2019

09:10-10:40 90'	SESSION 5 Locally advanced NSCLC	Chairs: Paul E. Van Schil, BE David Woolf, UK
30'	Treatment of locally advanced NSCLC in the elderly	David Woolf, UK
30'	Combined modality treatment for NSCLC with N2 disease	Clara Chan, UK
30'	Role of surgery for N2 disease	Paul E. Van Schil, BE
10:40-11:00	Coffee break	
11:00-12:00 60'	SESSION 5 Locally advanced NSCLC - cont.	Chairs: Paul E. Van Schil, BE David Cobben, UK
3x20'	3 x Participant clinical case discussion	Faculty
Each 20 min slot for clinical case discussion includes 10' case presentation and 10' Q&A / interactive panel discussion		
12:00-13:00	Lunch	
13:00-14:30 90'	SESSION 6 SCLC	Chairs: Pilar Garrido, ES David Cobben, UK
30'	Treatment of limited stage SCLC	David Cobben, UK
30'	Treatment of extensive stage SCLC	Martin Früh, CH
30'	Targeted agents in SCLC	Pilar Garrido, ES
14:30-14:50	Coffee break	
14:50-15:50 60'	SESSION 6 SCLC - cont.	Chairs: David Cobben, UK Raffaele Califano, UK
30'	Prophylactic cranial irradiation and role of thoracic RT for extensive stage SCLC	Neil Bayman, UK
30'	Versatility of circulating tumour cells in SCLC – biomarkers, biology, mouse models and drug development	Fiona Blackhall, UK
15:50-15:55 5'	Conclusion and farewell	Raffaele Califano, UK